Autonomic function in NMOSD and MS
Part of Brain & nervous system, Immune system & allergy clinical trials.
This study compares autonomic nervous system function in people with neuromyelitis optica spectrum disorder (NMOSD) and relapsing-remitting multiple sclerosis (RRMS). It aims to understand how these conditions affect automatic body functions like heart rate and digestion.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be 18 years or older
- Have a confirmed diagnosis of neuromyelitis optica spectrum disorder (NMOSD) or relapsing-remitting MS (RRMS)
- Do not have other conditions that affect autonomic function, such as diabetes or Parkinson's disease
- Not be taking medications that interfere with autonomic testing
- Be able to complete questionnaires without significant cognitive problems
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how the nervous system controls automatic body functions (like heart rate and blood pressure) in people with multiple sclerosis. Researchers want to compare results between people with MS and healthy volunteers to understand how MS affects these functions.
This study compares two conditions that affect the nervous system: multiple sclerosis (MS) and neuromyelitis optica spectrum disorder (NMOSD). Researchers want to understand differences between them, which may help with diagnosis and treatment.
This study looks at signs of how your automatic “control” nerves (the autonomic nervous system) may be affected in people with multiple sclerosis. It may help researchers better understand different types of MS and how to recognize nervous-system involvement.
This study follows people with NMOSD (a rare autoimmune disease that can cause vision loss and paralysis) to learn more about the condition. It may help doctors better understand and treat NMOSD in the future.
This observational study follows people with various immune-related neurological conditions, such as multiple sclerosis, neuromyelitis optica, and autoimmune encephalitis. It aims to better understand these diseases and their progression over time.
This study looks at patients with neuromyelitis optica spectrum disorder (NMOSD)—a rare condition affecting the nervous system—who are doing well on rituximab treatment. Researchers want to understand hidden signs of disease activity that might predict future problems, even when patients feel stable.
Hear when a new NMO and MS trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.